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The past two decades have seen an explosion in research that aims to understand how the dynamic 
interplay with the gut microbiota impacts host health and disease, establishing a role for the gut 
microbiota in a plethora of pathologies. Understanding how health‐promoting microbiota are 
established and how beneficial host–microbiota interactions are maintained is of immense 
biomedical importance. Despite the enormous progress that has been made, our knowledge of the 
specific microbiota members that mediate these effects and the mechanisms underlying these 
interactions is rudimentary. The dearth of information regarding the nature of advantageous host–
microbiota interactions, and the factors that cause these relationships to go awry, has hampered our 
ability to realize the therapeutic potential of the microbiota. Here we discuss key issues that limit 
current knowledge and describe a path forwards to improving our understanding of the 
contributions of the microbiota to host health. 
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The gut microbiota as a regulator of host health 
Born devoid of microbes, our intestines gradually become densely colonized by a complex collection 
of bacteria, eukaryotes, archaea and viruses that are collectively referred to as the gut microbiota. 
Rather than being mere passengers, the gut microbiota profoundly shapes many facets of host 
physiology, including aiding in the acquisition and provision of nutrients, educating the immune 
system, and providing resistance to invading pathogens.1, 2 Although interest in this complex 
ecosystem is often touted as new, the microbiota has proved a source of fascination for scientists for 
well over a century. Indeed, immunological interest in the role of the gut microbiota can be traced to 
Elie Metchnikoff, who was obsessed with how the gut microbiota could be detrimental to health, 
and how this could be remedied through administration of health‐promoting bacteria (probiotics), in 
the early twentieth century.3 Although study of the microbiota long‐remained a fringe area of 
research, a number of intrepid investigators continued to provide key insights into the contributions 
of our gut microbes to host health, laying the groundwork for modern microbiota research.4-8 The 
field was reinvigorated with the advent of new and improved approaches for characterizing the 
composition of the microbiota and provocative findings that suggested the microbiota could 
modulate susceptibility to an ever‐increasing variety of diseases. 
The development of next‐generation sequencing technologies, and analytic approaches accessible to 
non‐experts, provided researchers with the opportunity to interrogate the structure of complex 
microbial communities at an unprecedented scale, advancing earlier efforts to understand the 
microbial and viral ecology of the intestinal tract.6, 9-19 These approaches allowed researchers to 
define the microbiota composition from large numbers of individuals across time and geographical 
boundaries, at different developmental stages, and in response to a variety of perturbations.20-
22 These culture‐independent approaches, which continue to grow in scale and resolution, revealed 
that the microbiota reaches a relatively stable and functionally mature state by 3 years of age22 and 
exhibits large interpersonal variation,14, 23 with each individual carrying a largely unique set of strains 
that persist for extended periods of time.21, 24 Gut microbial community composition is modified by 
many environmental factors, such as geographical location,21, 22 host diet25 and administration of 
antibiotics26 and other medicines.27 Despite inter‐individual differences in community composition, a 
core set of genes shared across individuals is encoded by the microbiota, suggesting that distinct 
community compositions can provide similar functional outputs.13, 14 Strikingly, it was demonstrated 
that, relative to healthy controls, differences in microbial community structure (often termed 
dysbiosis) could be observed in individuals suffering from a variety of disorders including 
obesity,28, 29 inflammatory bowel disease (IBD),30-32 cardiovascular disease,33 malnutrition,34 and type 
2 diabetes,35 many of which had not previously been linked to the activity of microbes. Furthermore, 
transplantation of fecal microbiota from human donors with such diseases to recipient germ‐
free/gnotobiotic mice was shown to transmit features associated with the disease. This includes 
obesity,29 malnutrition,34, 36 autoimmunity,37, 38 food allergy39 and IBD,40, 41 providing proof of 
principle of a causal role for the microbiota in elicitation or exacerbation of disease. Hence, a picture 
emerged where the unique constellation of microbial strains within an individual represented a 
critical factor that, in conjunction with host genetics and environmental influences, could influence 
disease susceptibility. The finding that alterations in microbiota composition were not merely 
correlated with disease, but could play a causal role in the development of a number of distinct host 
pathologies captured the imagination of scientists and the public alike, placing the microbiota at the 
forefront of biomedical research. Furthermore, experimental studies demonstrating that ‘microbiota 
repair', through administration of complete fecal communities or select microbial taxa, could 
alleviate disease in both humans and mice,42, 43 highlighted the therapeutic potential of next‐
generation probiotics. This has led to a flurry of work from scientists in disparate fields to provide 
insight into the microbes responsible for modulating host health, and has allowed microbiota 
researchers to adopt a framework akin to Koch's Postulates44 for microbiota‐driven phenotypes. 
Immune modulation by the gut microbiota 
The gut microbiota profoundly impacts the phenotype and function of the host immune system, the 
details of which have been reviewed expertly elsewhere.2, 45-47 Germ‐free mice present with 
numerous immune defects, including impaired T‐cell differentiation and accumulation in the 
intestine,48-50 decreased production/secretion of immunoglobulin A (IgA),8, 51 reduced anti‐microbial 
peptide production,52 and elevated levels of systemic IgE.53 Importantly, many of these deficits can 
be reversed through administration of a fecal microbiota from murine and human donors, or their 
derived bacterial strains, as well as by fungi or viruses, reinforcing the potential contribution of non‐
bacterial members of the community.48, 49, 54-58 Although not the first description of 
immunomodulation by the microbiota, the discovery that different frequencies of T helper type 17 
(Th17) cells were present in the small intestine of C57BL/6 mouse substrains obtained from two 
different commercial vendors, and that this was attributable to the presence of a single microbe, 
segmented filamentous bacteria (SFB),49, 55, 56 prompted intensive efforts to identify additional 
microbes that could control the development of various arms of the immune system. Understanding 
the molecular basis of such microbiota–host interactions could provide a basis to develop novel 
agents that shape immune function in a targeted fashion to benefit host health. However, the 
massive complexity of the gut microbiota poses a daunting challenge to researchers, and identifying 
effector strains (microbial taxa that shape phenotypes of interest) remains a major goal for the field. 
Several different strategies have been used to overcome these difficulties and provide detailed 
insight into immune–microbiota interactions. 
Strategies to identify effector strains 
An optimal strategy to identify effector strains should have the following key features; (i) require no 
prior knowledge of the effector strain; (ii) not be focused solely on highly abundant community 
members; (iii) be agnostic to currently known functions of different taxonomic classifications; (iv) 
provide strain‐level resolution; and (v) be capable of identifying complex relationships where the 
effects of a particular microbe could be modified by other microbes.59, 60 
The primary strategy for identifying effector microbes involves approaches that compare community 
composition (membership and relative abundance) in a community that modifies immune function 
with one that does not. This has been employed successfully in the identification of SFB as a potent 
stimulator of the intestinal immune system.56 However, it has many limitations. First, strains whose 
abundance correlates with a phenotype of interest may not play causal roles in that 
phenotype.61 Second, comparing the structure of distinct microbial communities that imprint 
different host phenotypes may lead to the generation of a large list of taxa that are differentially 
represented and therefore, potentially mediating the phenotypic difference, making the 
identification of target agents a difficult task. An elegant solution to this problem uses co‐housing of 
mice that have been colonized with different microbiota that are associated with distinct 
phenotypes.62, 63 As co‐housing of different mice leads to incomplete exchange of gut microbiota, 
this approach generates ‘sublines' of mice harboring distinct mixtures of the two ‘parental' 
microbiota. By determining shared microbiota constituents that correlate with the phenotype of 
interest in the sublines and parental mice, the microbes responsible can be parsed in a more 
efficient fashion. Third, until recently, sequencing‐based studies lacked strain‐level resolution, and 
used ≥97% 16S rRNA gene sequence similarity as a proxy for identifying species. Yet, inferring 
function based on this level of taxonomic resolution is flawed given that strain‐level variation, where 
strains of a given species vary in their function or the host phenotypes they imprint, is a well‐
described feature of gut microbes (here we refer to strains as isolates of the same species that 
exhibit distinguishable genotypic or phenotypic characteristics64). For example, strains of Bacteroides 
fragilis that express the enterotoxin known as B. fragilis toxin can promote the development of 
colon cancer,65 colitis,66 and malnutrition‐associated cachexia,67 whereas B. fragilis toxin‐negative 
strains lack this capacity. Conversely, a non‐enterotoxigenic strain of B. fragilis is associated with the 
induction of regulatory T (Treg) cells and interleukin‐10 (IL‐10).68 This is not a peculiarity of B. fragilis, 
and profound differences linked to strain‐level variation among other gut bacteria have been 
documented.69 Hence, efforts to validate findings based on sequencing, which typically involves the 
use of a commercially available strain of the species of interest, may lead to use of strains lacking the 
desired activity, deeming the effort a failure. Finally, even when key effector strains/strain consortia 
can be identified, they may not be themselves sufficient and instead require the presence of specific 
additional community members for the phenotype to manifest. For example, in the ‘TRUC' model of 
transmissible colitis in T‐bet−/−RAG−/− mice, Klebsiella pneumoniae and Proteus mirabilis elicit the 
development of colitis, but only when in the presence of an endogenous microbial 
community.70 Similarly, while Helicobacter hepaticus induces robust typhlocolitis in IL‐10−/− mice, 
mono‐colonization of germ‐free IL‐10−/− mice with H. hepaticus is insufficient to promote intestinal 
pathology.71-73 Hence, microbes that do not vary between communities may be necessary to observe 
a phenotype and will be missed by sequencing‐dependent efforts. 
Another commonly employed approach involves the use of anti‐microbial agents to winnow the 
number of potential effector strains. These have included antibiotics that target specific classes of 
bacteria (i.e. Gram‐positive, Gram‐negative, anaerobes) and chloroform or ethanol treatment of 
intestinal material to enrich for spore‐forming bacteria, which have also proved to be of major utility 
in identifying modifiers of the immune system.48, 49, 54, 74, 75 However, such strategies are prone to 
some of the same issues listed above, and can preclude the identification of some complex 
relationships where distinct microbes must interact for a phenotype to manifest (for example if 
Gram‐negative and Gram‐positive bacteria cooperate). Moreover, some of these anti‐microbial 
agents can also affect host physiology, which can confound interpretation of their effects.76 Mono‐
colonization with large panels of microbes can also be used to determine their effects on host 
immune responses,77, 78 but such efforts require that the microbial taxa used are sufficient to 
promote the phenotype of interest, require the ability of the specific taxa used to successfully mono‐
colonize mice, and will miss scenarios where microbe–microbe interactions are key to imprinting 
phenotypic responses. 
More recently, researchers have developed and implemented newer, less biased approaches to 
address these limitations. The most fruitful of these methods involves assessing the coating of gut 
microbes with host‐derived IgA, the dominant antibody class in the gut lumen, to identify 
immunogenic microbes within a complex community (i.e. microbes coated with IgA). In this strategy, 
microbes from intestinal contents that are coated by host IgA are detected through flow cytometry 
and IgA‐positive and IgA‐negative fractions purified by fluorescence‐activated cell sorting are 
subjected to 16S rRNA gene sequencing for identification, or transferred to recipient gnotobiotic 
mice to determine their ability to transmit a phenotype36, 41, 79, 80 (Fig.1). Using this approach to study 
microbiota from individuals with IBD, it has been demonstrated that bacteria enriched in IgA coating 
support development of more severe dextran sodium sulfate‐induced colitis than non‐targeted 
bacteria, identifying putative candidates that modulate the susceptibility to IBD.41 A similar strategy 
identified a strain of Escherichia coli that was enriched for IgA targeting in microbiota from a subset 
of patients with Crohn's disease with spondyloarthritis and that could elicit potent activation of 
mucosal CD4+ T cells.81 IgA targeting was also able to identify pathogenic Enterobacteriaceae from 
the microbiota of a child suffering from Kwashiorkor (a form of severe acute edematous 
malnutrition) that could induce a high degree of mortality upon transplantation to gnotobiotic mice 
consuming a nutrient‐deficient diet. In addition, IgA‐targeted microbes from a healthy microbiota 
donor could in turn prevent this mortality phenotype, so pathogenic and protective microbes can be 
enriched for targeting by IgA and identified using this strategy.36 This suggested that IgA targeting 
generally reflects microbes with immune modulatory potential, rather than pathogenic strains per 
se. However, a recent systematic assessment of the specificities of intestinal IgA has revealed a large 
degree of polyreactivity, suggesting that binding by IgA may not actually be due to B‐cell stimulation 
by a given IgA‐coated target,82 but rather the expression of an epitope targeted by polyreactive IgA. 
Furthermore, this strategy captures only those microbes that have been bound by IgA, and microbes 
that evade antibody responses, or which shape immune responses without eliciting an immune 
response against themselves (for example, a microbe that enhances the fitness of a strongly 
immunogenic strain could alter immune responses in the gut without being recognized by the 
immune system) will not be detected using this approach. 
 
Figure 1- Identifying immunomodulatory microbes within the gut microbiota: As depicted above, newer strategies employ 
intensive culturing and microbiota subsetting, and/or IgA‐based identification of immunomodulatory microbes, followed by 
selective reconstitution of germ‐free mice, to map phenotypes to defined microbiota components. These efforts should 
provide key insights into the prominent modifiers of host immune phenotypes and help to develop next‐generation 
probiotics that beneficially manipulate immune function. 
One of us (PPA) recently developed a strategy, termed combinatorial gnotobiotics, that provides a 
more systematic assessment of the microbes that shape host phenotypes of interest.83 This 
approach (described in ref.59) involves isolation of microbial strains from a community of interest in 
clonally arrayed culture libraries,84 and administration of randomly selected microbial consortia of 
differing but known composition to gnotobiotic mice, to assess how individual microbes, either 
alone or together with other community members, modulate phenotypes of interest (Fig. 1). This 
strategy has the advantage of providing strain‐level resolution, requires no prior knowledge of the 
strain, is agnostic as to whether a host response targets the microbe, and by using subsets 
containing different numbers of microbes has the ability to identify higher‐order interactions where 
two or more strains cooperate or compete to elicit a response. This strategy effectively identified 
complex interactions that regulated the cecal metabolite pool, and identified greater redundancy in 
colonic Treg cell accumulation than had been previously appreciated.83 In addition to requiring a 
larger number of gnotobiotic mice than the other approaches discussed, a primary challenge of this 
strategy is the need to capture agents in pure culture, which would have missed the important 
contributions of SFB to mucosal immunity because of the difficulties associated with its 
cultivation.85 Although much maligned, recent years have witnessed a rebirth of culture‐based 
approaches to interrogate gut microbiota composition and function.74, 84, 86, 87 Resistance to culture‐
based strategies can be explained in part by the notion that much of the microbiota was 
‘unculturable'.87 A resurgence in efforts to culture these microbes, led by environmental 
microbiologists, has seen dramatic improvements in the proportion of the gut microbiota that can 
be isolated. In a landmark study, 212 different culturing conditions, involving perturbations to media 
composition, growth temperature and pH among other variables, were tested leading to the 
isolation of 340 bacterial species, many of which had not been previously found in the human 
gut.86 Importantly, just 20 different conditions were sufficient to isolate a majority of the strains, and 
it has been demonstrated by other groups that a great deal of the diversity within a given 
community can even be captured using a single rich medium,84, 88 enhancing the tractability of 
isolation efforts. As improvements continue to be made in culturability, aided by metagenomics‐
based identification of potential growth factors, isolation of strains of interest will likely be less 
problematic, thereby advancing studies that begin with a culture‐based step. 
Clearly, no single approach encompasses all the discovery features required for a truly unbiased and 
fully systematic approach, nor are any of these strategies suited to all questions. Instead, leveraging 
the advantages of these different approaches may provide an optimal way towards increasing our 
understanding of gut microbiota regulation of immune function. As a proof‐of‐principle of the utility 
of combining these strategies, studies merging the power of sequencing of IgA‐bound bacteria with 
isolation in culture and phenotypic assessment in gnotobiotic mice, have already been employed to 
identify potential harmful and beneficial bacterial taxa.36, 41 
Of mice and men 
An important facet of gut microbiota research using gnotobiotic mice involves the decision about 
whether to study microbes derived from humans or those obtained from mice (Fig.2). The rationale 
for studying human‐derived microbes is self‐evident, in that it appears more translationally relevant. 
Microbial communities from humans with various diseases of interest can be assessed for their 
capacity to transmit disease susceptibility and microbes implicated in the modulation of human 
health can be identified.[29, 34, 36-42] This approach has led to the successful identification of the gut 
microbiota as a critical regulator of a variety of diseases, and defined specific human‐derived 
microbial taxa that can shape the host immune system.54, 83 However, a number of caveats exist that 
should be considered. First, many human‐associated microbial taxa poorly colonize mice, if at all, 
and the relative abundance of those taxa that do successfully colonize may poorly reflect that 
observed in the donor community.25, 89 The study of a complex human microbiota in gnotobiotic 
mice may therefore significantly overstate or underestimate the contributions of particular taxa to 
phenotypes of interest. Second, human‐derived fecal microbiota communities may be less well 
adapted to the mouse intestine. When mice harboring a human‐derived or mouse‐derived fecal 
microbiota were co‐housed to facilitate exchange of their respective microbiota, many strains from 
the murine‐derived community were effectively able to invade the human‐derived gut microbiota 
and stably establish themselves, while the members of the human‐derived community were largely 
unable to establish themselves within the murine community.90 These data suggest that although 
human‐derived microbiota can form a stable community within a gnotobiotic mouse, they lack 
fitness in this environment relative to the murine community. Finally, host specificity in host–
microbe interactions is a long‐appreciated phenomenon (particularly in microbial 
pathogenesis)91 and individual microbial taxa may have evolved to stimulate or evade the immune 
system of the host in which they normally reside. Isolates of SFB from mice and rats have shown 
exquisite specificity in the induction of intestinal Th17 responses, with rat‐derived SFB priming Th17 
responses in the rat but not the mouse, and mouse‐derived SFB priming Th17 responses in the 
mouse but not the rat.92 Moreover, some human‐derived fecal microbiota were demonstrated to be 
poor stimulators of immune system maturation in selected lymphoid and non‐lymphoid sites in 
gnotobiotic mice, providing reduced resistance to pathogenic intestinal infection when compared 
with the recipients of murine fecal microbiota.55, 89 We posit that much may be learned about human 
immune interactions with their endogenous microbiota by comparatively studying other microbial 
communities in their natural habitat, i.e. the study of murine‐derived microbiota in the mouse 
intestine may better delineate shared paradigms of host–microbiota interactions than the study of 
human‐derived microbiota in gnotobiotic mice. This is not to suggest precluding the study of human‐
derived microbes in mice, from which we have already learned much,25, 34, 36, 40-42, 50, 54, 83 but instead 
calls for judicious interpretation of data using such microbes. Indeed, study of the molecular basis by 
which human‐derived microbiota adapt and evolve during colonization and long‐term residence of 
the mouse intestine, in addition to delineating differences in the shaping of immune responses, 
represents a powerful strategy to uncover key facets of host–microbiota interplay. Complimentary 
approaches to the discovery process are also necessary given the mouse‐intensive nature of most 
current strategies and the fact that important human–microbiota interactions may not be modeled 
in a murine system. For example, primary intestinal organoids represent a particularly useful tool to 
study human epithelium–microbe interactions for several reasons, including: they can be generated 
directly from humans (with or without disease‐associated genetic polymorphisms); they can be 
genetically modified using clustered regularly interspaced short palindromic repeats (CRISPR)/Cas 
technology; they recapitulate important epithelial cell lineages and physical features of the intestinal 
tract; and they can be seeded with microbes of interest.93 Another promising approach is to identify 
factors like metabolites that can impact a response of interest and work to identify the microbes 
that are responsible for their production.94, 95 As knowledge of the key mechanisms of host–
microbiota interactions are revealed, our accuracy in predicting immunomodulatory activity based 
on the genomic content of a strain or community should markedly improve. 
 
Figure 2 - Optimizing microbial communities to model microbiota–host interactions: The best source of gut microbiota to 
allow faithful modeling in mice of human host–microbiota interactions remains an important question. Recent work 
suggests that human‐derived microbiota do not fully recapitulate the immune phenotype seen using murine‐derived 
communities. In addition, the gut microbiota harbored by ‘wild' (feral) mice may imprint a mature immune phenotype more 
comparable to that of adult humans than to the immature immune system found in common laboratory mice, priming 
development of more activated CD8+ T cells and providing increased resistance to weight loss induced by treatment with 
azoxymethane plus dextran sodium sulfate. Identification of the mechanisms that underlie these phenomena will 
facilitate the development of microbial consortia that allow more accurate representation of human physiology in 
laboratory mice. 
Using the elegant approaches discussed above, the identity of specific microbes with potent 
immunomodulatory activity has been elucidated, especially those that shape the intestinal T‐cell 
compartment. A variety of bacterial strains from distinct phyla, operating individually or as part of 
multi‐strain consortia, prime the accumulation of peripherally derived colonic Treg cells and the 
production of the immune suppressive cytokine IL‐10. These include Clostridia from clusters IV, XIVa 
and XVIII (Firmicutes),48, 54 various Bacteroides species 
(Bacteroidetes)68, 78, 83, 96 or Helicobacter species (Proteobacteria),97-99 Bifidobacterium 
bifidum (Actinobacteria),100 and the Altered Schaedler Flora (multiple phyla).101 An isolate 
of Bifidobacterium adolescentis (an Actinobacteria) obtained from humans that could induce Th17 
cells was also identified, confirming that this was not unique to SFB.102 A cocktail of human‐derived 
strains from multiple phyla promote the development of interferon‐γ‐secreting CD8+ T cells50 and 
intraepithelial lymphocytes are also potently regulated by gut microbes, with a murine‐derived 
strain of Lactobacillus reuteri shown to elicit intraepithelial CD4+CD8αα+ T‐cell generation,75 while 
SFB is known to increase T‐cell receptor αβ‐positive intraepithelial lymphocytes.51 Mechanistically, 
microbial metabolites have been shown to mediate many of these effects. Short‐chain fatty acids, 
products of microbial fermentation in the gut, promote Treg cell accumulation,103-105 in addition to 
regulating many other immune effector functions.106-108 Microbiota‐derived ATP can stimulate Th17 
development,109 and tryptophan breakdown products like indole‐3‐lactic acid promote the 
development of intraepithelial CD4+CD8αα+ T cells through stimulation of the aryl hydrocarbon 
receptor.75 Bacterially derived polysaccharides such as polysaccharide A from B. fragilis,68 β‐
glucan/galactan polysaccharides from Bifidobacterium bifidum100 or crude carbohydrate 
preparations from H. hepaticus110 can prime Treg or IL‐10 production. Intriguingly, atypical antigen 
acquisition pathways111 have also been shown to be important for SFB‐induced Th17 development. 
Collectively, these studies demonstrate that the intestinal immune system can be activated by a 
diverse array of microbial taxa through a variety of distinct mechanisms, highlighting a large degree 
of redundancy in the processes which help to maintain these mutualistic relationships. Interestingly, 
some of the microbial taxa that impart beneficial effects on the immune system have also been 
implicated in the pathogenesis of inflammatory disease models, and so rather than being inherently 
beneficial, their positive effects are dependent on host factors and the context of the 
interaction.61, 112-115 Additionally, an important time‐window where colonization must take place has 
also been established for particular phenotypes, emphasizing the importance not just of exposure to 
select microbes, but of encounter at the appropriate developmental stage.116-118 Given the shorter 
lifespan of mice relative to humans, it will be critical to determine how such developmental windows 
translate between species, and the consequences for interventions that aim to repair poorly 
developed or damaged microbiota for therapy. 
Developing a consistent approach to assessing microbiota effects 
The identification of select microbial taxa that modulate various arms of the intestinal immune 
system that have variable presence in mouse facilities49, 75, 99, 119 points to an unwanted source of 
variability in mouse models, highlighting the need for more defined microbiota to facilitate 
comparison of data across different laboratories. Although co‐housing of different groups of mice 
has been reported to be able to transfer microbiota‐dependent phenotypes in many instances, as 
noted above, the exchange of microbiota between adult mice is incomplete. In the absence of 
gnotobiotic facilities, current best practice for minimizing microbiota variables recommends using 
heterozygous or wild‐type littermate controls in studies of genetically modified mice, as well as 
standardizing housing conditions and diets across experimental groups.120 In addition, pedigrees can 
be tracked, to enable retrospective analysis of ‘cage effects' that may have arisen as the result of 
distinct parental microbiota. However, these processes will not homogenize microbiota across 
breeding cohorts in different specific‐pathogen‐free (SPF) facilities, meaning that phenotypes that 
can be influenced by microbiota may not appear readily reproducible. Indeed, for the purposes of 
knowledge discovery, it could be argued that global homogeneity is undesirable, as such 
discrepancies provide a basis for identifying microbiota constituents that regulate 
phenotypes.56, 75 As an example, one can consider the conflicting reports on the incidence of 
spontaneous intestinal inflammation in Tlr5−/− mice121, 122 or dextran sodium sulfate‐induced colitis 
susceptibility in Nlrp6−/− mice,123-125 highlighting the contextual expression of these phenotypes 
depending on environmental factors. 
In addition to variability in microbiota, another caveat of using laboratory mice to model the human 
immune system was highlighted by the finding that the immune system of adult laboratory mice 
housed under SPF conditions is phenotypically representative of a newborn's immature immune 
system, in contrast to the mature immune system found in adult mice living in the wild or in pet 
stores.126 The adult‐like immune phenotype of wild or pet‐store mice has been linked to infectious 
agents,127 but a gut microbiota from wild mice, devoid of known mouse pathogens, also beneficially 
modified the response of gnotobiotic mice to infectious or chemical insult, relative to a microbiota 
derived from SPF laboratory mice.128 Hence, although the SPF mouse has been of enormous value in 
removing confounding variables like infections, a reassessment of the optimal microbiota 
composition for laboratory mice appears to be in order (Fig. 2). 
Crucially, SPF conditions are currently defined by the absence of specific pathogenic microbes rather 
than being defined by the microbes that are present. Furthermore, the precise criteria used to 
classify colonies as SPF varies among vendors and facilities, with many potent immunomodulatory 
microbial taxa, such as SFB and Helicobacter spp., not routinely included in the list of proscribed 
microbes. New microbial cocktails containing known immunomodulatory microbes as noted above, 
in addition to non‐pathogens found in wild mice that shape host physiology (yet to be described), 
could be developed and used similarly to the Altered Schaedler Flora129 to provide the consistency 
desired by researchers, while improving the translatability of mouse systems. However, this 
approach poses many challenges. For example, developing a consensus as to which microbes should 
be used in such a cocktail and implementing strategies that allow for maintenance of these microbes 
without the invasion of true pathogens or other immunomodulatory microbes, is far from simple. 
Generation and characterization of purified stable consortia, potentially composed of bacteria, fungi 
or viruses that provide a more homogeneous microbiota, driving a consistent level of immune 
maturation that more accurately reflects the immune‐activation levels in adult humans, is an 
essential first step. It is very likely that there will not be a single microbiota type that is relevant for 
all questions, and the most appropriate community will critically depend on the human population 
to be modeled, as well as the environmental challenges under investigation. However, the 
community should be fully characterized, should have minimal variance over time and should reflect 
the human population to be studied as closely as possible. These consortia could then be used to 
regularly seed breeder colonies to help ensure their sustained presence within a colony, but the 
large‐scale feasibility of such an approach and the precise protocols required to ensure consistent 
microbiota composition remain to be fully determined. Furthermore, this approach would require 
careful monitoring, maintenance of high levels of hygiene and husbandry and strict control of diet. 
The expansion of gnotobiotic facilities will likely expedite the generation of new ‘minimal essential' 
stable consortia, with parallel characterization of the level of immune maturation in the murine host. 
In the meantime, in addition to the breeding and husbandry strategies outlined above, investigators 
should consider reporting the composition of the microbiota of mice used in their studies wherever 
possible. Much in the same way that sentinel mice are used to declare a colony as SPF, assessment 
of the microbiota of sentinels using 16S rRNA gene sequencing or shotgun metagenomic sequencing 
could be reported in published manuscripts, addressing an important variable that could lead to 
issues associated with reproducibility of data. Of course, because of constraints in resources and 
infrastructure, this reporting is unlikely to be feasible in all cases, but as sequencing costs reduce and 
bioinformatic training becomes more routine, reporting of microbiota composition should become a 
standard practice in many institutes. In addition, making such data available should also facilitate in 
silico approaches by other investigators to identify potential members, or interacting cohorts of 
microbes, that regulate immune maturation or experimental phenotypes. Together, such efforts will 
iteratively improve our understanding of how microbiota shape host immunity and disease 
phenotypes. 
Conclusion 
We are at an exciting time in microbiota research, with an increasing number of diseases being 
connected to the dynamic functions of the microbiota. The next steps, including the development of 
novel probiotic strains to treat disease, will require detailed understanding of the most beneficial 
microbes for host health, the context in which they operate, and molecular‐level details 
underpinning these effects. Indeed, with the strategies described here, allied to efforts to 
characterize the mechanisms of action of the microbiota and microbiota‐derived products in health 
and disease, we are well on our way. 
Acknowledgements 
We thank Anagha Kadam, Morgan Engelhart and Naseer Sangwan for helpful comments. We 
apologize to the many researchers whose outstanding work we did not cite because of space 
constraints. KJM is supported by a Wellcome Trust Investigator Award (102972). We dedicate this 
review to our late friend and colleague, Dr. Mark Asquith, who helped shape our thinking on 
microbiota–host interactions and many other topics. 
Disclosures 




1 Hooper LV, Midtvedt T, Gordon JI. How host–microbial interactions shape the nutrient 
environment of the mammalian intestine. Annu Rev Nutr 2002; 22: 283– 307. 
  
2 Smith K, McCoy KD, Macpherson AJ. Use of axenic animals in studying the adaptation of mammals 
to their commensal intestinal microbiota. Semin Immunol 2007; 19: 59– 69. 
  
3 Mackowiak PA. Recycling metchnikoff: probiotics, the intestinal microbiome and the quest for long 
life. Front Public Health 2013; 1: 52. 
  
4 Orcutt RP, Gianni FJ, Judge RJ. Development of an Altered Schaedler Flora for Nci gnotobiotic 
rodents. Microecol Ther 1987; 17: 59. 
  
5 Reyniers JA, Sacksteder MR. The use of germfree animals and techniques in the search for 
unknown etiological agents. Ann N Y Acad Sci 1958; 73: 344– 56. 
  
6 Savage DC. Microbial ecology of the gastrointestinal tract. Annu Rev Microbiol 1977; 31: 107– 33. 
  
7 Schaedler RW, Dubs R, Costello R. Association of Germfree mice with bacteria isolated from 
normal mice. J Exp Med 1965; 122: 77– 82. 
  
8 Talham GL, Jiang HQ, Bos NA, Cebra JJ. Segmented filamentous bacteria are potent stimuli of a 
physiologically normal state of the murine gut mucosal immune system. Infect Immun 1999; 67: 
1992– 2000. 
  
9 Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK et al. QIIME allows 
analysis of high‐throughput community sequencing data. Nat Methods 2010; 7: 335– 6. 
  
10 Eckburg PB, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, Sargent M et al. Diversity of the 
human intestinal microbial flora. Science 2005; 308: 1635– 8. 
  
11 Hamady M, Walker JJ, Harris JK, Gold NJ, Knight R. Error‐correcting barcoded primers for 
pyrosequencing hundreds of samples in multiplex. Nat Methods 2008; 5: 235– 7. 
  
12 Kuczynski J, Costello EK, Nemergut DR, Zaneveld J, Lauber CL, Knights D et al. Direct sequencing of 
the human microbiome readily reveals community differences. Genome Biol 2010; 11: 210. 
  
13 Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C et al. A human gut microbial gene 
catalogue established by metagenomic sequencing. Nature 2010; 464: 59– 65. 
  
14 Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, Ley RE et al. A core gut 
microbiome in obese and lean twins. Nature 2009; 457: 480– 4. 
  
15 Breitbart M, Hewson I, Felts B, Mahaffy JM, Nulton J, Salamon P et al. Metagenomic analyses of 
an uncultured viral community from human feces. J Bacteriol 2003; 185: 6220– 3. 
  
16 Minot S, Sinha R, Chen J, Li H, Keilbaugh SA, Wu GD et al. The human gut virome: inter‐
individual variation and dynamic response to diet. Genome Res 2011; 21: 1616– 25. 
  
17 Nash AK, Auchtung TA, Wong MC, Smith DP, Gesell JR, Ross MC et al. The gut mycobiome of the 
human microbiome project healthy cohort. Microbiome 2017; 5: 153. 
  
18 Reyes A, Haynes M, Hanson N, Angly FE, Heath AC, Rohwer F et al. Viruses in the faecal 
microbiota of monozygotic twins and their mothers. Nature 2010; 466: 334– 8. 
  
19 Scupham AJ, Presley LL, Wei B, Bent E, Griffith N, McPherson M et al. Abundant and diverse 
fungal microbiota in the murine intestine. Appl Environ Microbiol 2006; 72: 793– 801. 
  
20 Dominguez‐Bello MG, Costello EK, Contreras M, Magris M, Hidalgo G, Fierer N et al. Delivery 
mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in 
newborns. Proc Natl Acad Sci U S A 2010; 107: 11971– 5. 
  
21 Pasolli E, Asnicar F, Manara S, Zolfo M, Karcher N, Armanini F et al. Extensive unexplored human 
microbiome diversity revealed by over 150,000 genomes from metagenomes spanning age, 
geography, and lifestyle. Cell 2019; 176: e20. 
  
22 Yatsunenko T, Rey FE, Manary MJ, Trehan I, Dominguez‐Bello MG, Contreras M et al. Human gut 
microbiome viewed across age and geography. Nature 2012; 486: 222– 7. 
  
23 Schloissnig S, Arumugam M, Sunagawa S, Mitreva M, Tap J, Zhu A et al. Genomic variation 
landscape of the human gut microbiome. Nature 2013; 493: 45– 50. 
  
24 Faith JJ, Guruge JL, Charbonneau M, Subramanian S, Seedorf H, Goodman AL et al. The long‐
term stability of the human gut microbiota. Science 2013; 341:1237439. 
  
25 Turnbaugh PJ, Ridaura VK, Faith JJ, Rey FE, Knight R, Gordon JI. The effect of diet on the human 
gut microbiome: a metagenomic analysis in humanized gnotobiotic mice. Sci Transl Med 2009; 1: 
6ra14. 
  
26 Dethlefsen L, Huse S, Sogin ML, Relman DA. The pervasive effects of an antibiotic on the human 
gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol 2008; 6: e280. 
  
27 Forslund K, Hildebrand F, Nielsen T, Falony G, Le Chatelier E, Sunagawa S et al. Disentangling type 
2 diabetes and metformin treatment signatures in the human gut microbiota. Nature 2015; 528: 
262– 6. 
  
28 Ley RE, Bäckhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI. Obesity alters gut microbial 
ecology. Proc Natl Acad Sci U S A 2005; 102: 11070– 5. 
  
29 Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity‐associated 
gut microbiome with increased capacity for energy harvest. Nature 2006; 444: 1027– 31. 
  
30 Frank DN, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR. Molecular‐phylogenetic 
characterization of microbial community imbalances in human inflammatory bowel diseases. Proc 
Natl Acad Sci U S A 2007; 104: 13780– 5. 
  
31 Gevers D, Kugathasan S, Denson LA, Vázquez‐Baeza Y, Van Treuren W, Ren B et al. The 
treatment‐naive microbiome in new‐onset Crohn's disease. Cell Host Microbe 2014; 15: 382– 
392. 
  
32 Manichanh C, Rigottier‐Gois L, Bonnaud E, Gloux K, Pelletier E, Frangeul L et al. Reduced 
diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. Gut 2006; 55: 
205– 11. 
  
33 Kelly TN, Bazzano LA, Ajami NJ, He H, Zhao J, Petrosino JF et al. Gut microbiome associates with 
lifetime cardiovascular disease risk profile among Bogalusa heart study participants. Circ Res 2016; 
119: 956– 64. 
  
34 Smith MI, Yatsunenko T, Manary MJ, Trehan I, Mkakosya R, Cheng J et al. Gut microbiomes of 
Malawian twin pairs discordant for kwashiorkor. Science 2013; 339: 548– 54. 
  
35 Qin J et al. A metagenome‐wide association study of gut microbiota in type 2 diabetes. Nature 
2012; 490: 55– 60. 
  
36 Kau AL, Planer JD, Liu J, Rao S, Yatsunenko T, Trehan I et al. Functional characterization of IgA‐
targeted bacterial taxa from undernourished Malawian children that produce diet‐dependent 
enteropathy. Sci Transl Med 2015; 7: 276ra24. 
  
37 Berer K, Gerdes LA, Cekanaviciute E, Jia X, Xiao L, Xia Z et al. Gut microbiota from multiple 
sclerosis patients enables spontaneous autoimmune encephalomyelitis in mice. Proc Natl Acad Sci U 
S A 2017; 114: 10719– 24. 
  
38 Cekanaviciute E, Yoo BB, Runia TF, Debelius JW, Singh S, Nelson CA et al. Gut bacteria from 
multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models. Proc 
Natl Acad Sci U S A 2017; 114: 10713– 18. 
  
39 Feehley T, Plunkett CH, Bao R, Choi Hong SM, Culleen E, Belda‐Ferre P et al. Healthy infants 
harbor intestinal bacteria that protect against food allergy. Nat Med 2019; 25: 448– 53. 
  
40 Britton GJ, Contijoch EJ, Mogno I, Vennaro OH, Llewellyn SR, Ng R et al. Microbiotas from humans 
with inflammatory bowel disease alter the balance of Gut Th17 and RORγt+ regulatory T cells and 
exacerbate colitis in mice. Immunity 2019; 50: e4. 
  
41 Palm NW, de Zoete MR, Cullen TW, Barry NA, Stefanowski J, Hao L et al. Immunoglobulin A 
coating identifies colitogenic bacteria in inflammatory bowel disease. Cell 2014; 158: 1000– 10. 
  
42 Blanton LV, Charbonneau MR, Salih T, Barratt MJ, Venkatesh S, Ilkaveya O et al. Gut bacteria that 
prevent growth impairments transmitted by microbiota from malnourished children. Science 2016; 
351:aad3311. 
  
43 van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM et al. Duodenal 
infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013; 368: 407– 15. 
  
44 Neville BA, Forster SC, Lawley TD. Commensal Koch's postulates: establishing causation in human 
microbiota research. Curr Opin Microbiol 2018; 42: 47– 52. 
  
45 Honda K, Littman DR. The microbiome in infectious disease and inflammation. Annu Rev Immunol 
2012; 30: 759– 95. 
  
46 Honda K, Littman DR. The microbiota in adaptive immune homeostasis and disease. Nature 2016; 
535: 75– 84. 
  
47 Ost KS, Round JL. Communication between the microbiota and mammalian immunity. Annu Rev 
Microbiol 2018; 72: 399– 422. 
  
48 Atarashi K, Tanoue T, Shima T, Imaoka A, Kuwahara T, Momose Y et al. Induction of colonic 
regulatory T cells by indigenous Clostridium species. Science 2011; 331: 337– 41. 
  
49 Ivanov II, Frutos Rde L, Manel N, Yoshinaga K, Rifkin DB, Sartor RB et al. Specific microbiota direct 
the differentiation of IL‐17‐producing T‐helper cells in the mucosa of the small intestine. Cell 
Host Microbe 2008; 4: 337– 49. 
  
50 Tanoue T, Morita S, Plichta DR, Skelly AN, Suda W, Sugiura Y et al. A defined commensal 
consortium elicits CD8 T cells and anti‐cancer immunity. Nature 2019; 565: 600– 5. 
  
51 Umesaki Y, Setoyama H, Matsumoto S, Imaoka A, Itoh K. Differential roles of segmented 
filamentous bacteria and clostridia in development of the intestinal immune system. Infect Immun 
1999; 67: 3504– 11. 
  
52 Cash HL, Whitham CV, Behrendt CL, Hooper LV. Symbiotic bacteria direct expression of an 
intestinal bactericidal lectin. Science 2006; 313: 1126– 30. 
  
53 Cahenzli J, Köller Y, Wyss M, Geuking MB, McCoy KD. Intestinal microbial diversity during early‐
life colonization shapes long‐term IgE levels. Cell Host Microbe 2013; 14: 559– 70. 
  
54 Atarashi K, Tanoue T, Oshima K, Suda W, Nagano Y, Nishikawa H et al. Treg induction by a 
rationally selected mixture of Clostridia strains from the human microbiota. Nature 2013; 500: 232– 
6. 
  
55 Gaboriau‐Routhiau V, Rakotobe S, Lécuyer E, Mulder I, Lan A, Bridonneau C et al. The key role of 
segmented filamentous bacteria in the coordinated maturation of gut helper T cell responses. 
Immunity 2009; 31: 677– 89. 
  
56 Ivanov II, Atarashi K, Manel N, Brodie EL, Shima T, Karaoz U et al. Induction of intestinal Th17 cells 
by segmented filamentous bacteria. Cell 2009; 139: 485– 98. 
  
57 Kernbauer E, Ding Y, Cadwell K. An enteric virus can replace the beneficial function of commensal 
bacteria. Nature 2014; 516: 94– 8. 
  
58 Shao TY, Ang WXG, Jiang TT, Huang FS, Andersen H, Kinder JM et al. Commensal Candida albicans 
positively calibrates systemic Th17 immunological responses. Cell Host Microbe 2019; 25: e6. 
  
59 Ahern PP, Faith JJ, Gordon JI. Mining the human gut microbiota for effector strains that shape the 
immune system. Immunity 2014; 40: 815– 23. 
  
60 Rosen CE, Palm NW. Functional Classification of the Gut Microbiota: the key to cracking the 
microbiota composition code: functional classifications of the gut microbiota reveal previously 
hidden contributions of indigenous gut bacteria to human health and disease. BioEssays 2017; 
39:1700032. 
  
61 Bloom SM, Bijanki VN, Nava GM, Sun L, Malvin NP, Donermeyer DL et al. Commensal Bacteroides 
species induce colitis in host‐genotype‐specific fashion in a mouse model of inflammatory bowel 
disease. Cell Host Microbe 2011; 9: 390– 403. 
  
62 Surana NK, Kasper DL. Moving beyond microbiome‐wide associations to causal microbe 
identification. Nature 2017; 552: 244– 47. 
  
63 Ridaura VK, Faith JJ, Rey FE, Cheng J, Duncan AE, Kau AL et al. Gut microbiota from twins 
discordant for obesity modulate metabolism in mice. Science 2013; 341:1241214. 
  
64 Dijkshoorn L, Ursing BM, Ursing JB. Strain, clone and species: comments on three basic concepts 
of bacteriology. J Med Microbiol 2000; 49: 397– 401. 
  
65 Wu S, Rhee KJ, Albesiano E, Rabizadeh S, Wu X, Yen HR et al. A human colonic commensal 
promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med 2009; 15: 
1016– 22. 
  
66 Rhee KJ, Wu S, Wu X, Huso DL, Karim B, Franco AA et al. Induction of persistent colitis by a human 
commensal, enterotoxigenic Bacteroides fragilis, in wild‐type C57BL/6 mice. Infect Immun 2009; 
77: 1708– 18. 
  
67 Wagner VE, Dey N, Guruge J, Hsiao A, Ahern PP, Semenkovich NP et al. Effects of a gut pathobiont 
in a gnotobiotic mouse model of childhood undernutrition. Sci Transl Med 2016; 8: 366ra164. 
  
68 Round JL, Mazmanian SK. Inducible Foxp3+ regulatory T‐cell development by a commensal 
bacterium of the intestinal microbiota. Proc Natl Acad Sci U S A 2010; 107: 12204– 9. 
  
69 Arthur JC, Perez‐Chanona E, Mühlbauer M, Tomkovich S, Uronis JM, Fan TJ et al. Intestinal 
inflammation targets cancer‐inducing activity of the microbiota. Science 2012; 338: 120– 3. 
  
70 Garrett WS, Gallini CA, Yatsunenko T, Michaud M, DuBois A, Delaney ML et al. Enterobacteriaceae 
act in concert with the gut microbiota to induce spontaneous and maternally transmitted colitis. Cell 
Host Microbe 2010; 8: 292– 300. 
  
71 Dieleman LA, Arends A, Tonkonogy SL, Goerres MS, Craft DW, Grenther W et al. Helicobacter 
hepaticus does not induce or potentiate colitis in interleukin‐10‐deficient mice. Infect Immun 
2000; 68: 5107– 13. 
  
72 Nagalingam NA, Robinson CJ, Bergin IL, Eaton KA, Huffnagle GB, Young VB. The effects of 
intestinal microbial community structure on disease manifestation in IL‐10–/– mice infected 
with Helicobacter hepaticus. Microbiome 2013; 1: 15. 
  
73 Whary MT, Taylor NS, Feng Y, Ge Z, Muthupalani S, Versalovic J et al. Lactobacillus reuteri 
promotes Helicobacter hepaticus‐associated typhlocolitis in gnotobiotic B6.129P2‐IL‐
10(tm1Cgn) (IL‐10–/–) mice. Immunology 2011; 133: 165– 78. 
  
74 Browne HP, Forster SC, Anonye BO, Kumar N, Neville BA, Stares MD et al. Culturing of 
'unculturable' human microbiota reveals novel taxa and extensive sporulation. Nature 2016; 533: 
543– 46. 
  
75 Cervantes‐Barragan L, Chai JN, Tianero MD, Di Luccia B, Ahern PP, Merriman J et al. 
Lactobacillus reuteri induces gut intraepithelial CD4+CD8αα+ T cells. Science 2017; 357: 806– 10. 
  
76 Yang JH, Bhargava P, McCloskey D, Mao N, Palsson BO, Collins JJ. Antibiotic‐induced changes to 
the host metabolic environment inhibit drug efficacy and alter immune function. Cell Host Microbe 
2017; 22: e3. 
  
77 Geva‐Zatorsky N, Sefik E, Kua L, Pasman L, Tan TG, Ortiz‐Lopez A et al. Mining the human gut 
microbiota for immunomodulatory organisms. Cell 2017; 168: e11. 
  
78 Sefik E, Geva‐Zatorsky N, Oh S, Konnikova L, Zemmour D, McGuire AM et al. Individual intestinal 
symbionts induce a distinct population of RORγ+ regulatory T cells. Science 2015; 349: 993– 7. 
  
79 Bunker JJ, Flynn TM, Koval JC, Shaw DG, Meisel M, McDonald BD et al. Innate and adaptive 
humoral responses coat distinct commensal bacteria with immunoglobulin A. Immunity 2015; 43: 
541– 53. 
  
80 Kawamoto S, Maruya M, Kato LM, Suda W, Atarashi K, Doi Y et al. Foxp3+ T cells regulate 
immunoglobulin a selection and facilitate diversification of bacterial species responsible for immune 
homeostasis. Immunity 2014; 41: 152– 65. 
  
81 Viladomiu M, Kivolowitz C, Abdulhamid A, Dogan B, Victorio D, Castellanos JG et al. Escherichia 
coli enriched in Crohn's disease spondyloarthritis promote TH17‐dependent inflammation. Sci 
Transl Med 2017; 9:eaaf9655. 
  
82 Bunker JJ, Erickson SA, Flynn TM, Henry C, Koval JC, Meisel M et al. Wilson PC. Natural 
polyreactive IgA antibodies coat the intestinal microbiota. Science 2017; 358:eaan6619. 
  
83 Faith JJ, Ahern PP, Ridaura VK, Cheng J, Gordon JI. Identifying gut microbe–host phenotype 
relationships using combinatorial communities in gnotobiotic mice. Sci Transl Med 2014; 6: 220ra11. 
  
84 Goodman AL, Kallstrom G, Faith JJ, Reyes A, Moore A, Dantas G et al. Extensive personal human 
gut microbiota culture collections characterized and manipulated in gnotobiotic mice. Proc Natl Acad 
Sci U S A 2011; 108: 6252– 7. 
  
85 Schnupf P, Gaboriau‐Routhiau V, Gros M, Friedman R, Moya‐Nilges M, Nigro G et al. Growth 
and host interaction of mouse segmented filamentous bacteria in vitro. Nature 2015; 520: 99– 103. 
  
86 Lagier JC, Armougom F, Million M, Hugon P, Pagnier I, Robert C et al. Microbial culturomics: 
paradigm shift in the human gut microbiome study. Clin Microbiol Infect 2012; 18: 1185– 93. 
  
87 Lagier JC, Dubourg G, Million M, Cadoret F, Bilen M, Fenollar F et al. Culturing the human 
microbiota and culturomics. Nat Rev Microbiol 2018; 16: 540– 50. 
  
88 Forster SC, Kumar N, Anonye BO, Almeida A, Viciani E, Stares MD et al. A human gut bacterial 
genome and culture collection for improved metagenomic analyses. Nat Biotechnol 2019; 37: 186– 
92. 
  
89 Chung H, Pamp SJ, Hill JA, Surana NK, Edelman SM, Troy EB et al. Gut immune maturation 
depends on colonization with a host‐specific microbiota. Cell 2012; 149: 1578– 93. 
  
90 Seedorf H, Griffin NW, Ridaura VK, Reyes A, Cheng J, Rey FE et al. Bacteria from diverse habitats 
colonize and compete in the mouse gut. Cell 2014; 159: 253– 66. 
  
91 Baumler A, Fang FC. Host specificity of bacterial pathogens. Cold Spring Harb Perspect Med 2013; 
3:a010041. 
  
92 Atarashi K, Tanoue T, Ando M, Kamada N, Nagano Y, Narushima S et al. Th17 cell induction by 
adhesion of microbes to intestinal epithelial cells. Cell 2015; 163: 367– 80. 
  
93 Fujii M, Clevers H, Sato T. Modeling human digestive diseases with CRISPR‐Cas9‐modified 
organoids. Gastroenterology 2019; 156: 562– 76. 
  
94 Koeth RA, Lam‐Galvez BR, Kirsop J, Wang Z, Levison BS, Gu X et al. l‐Carnitine in omnivorous 
diets induces an atherogenic gut microbial pathway in humans. J Clin Invest 2019; 129: 373– 87. 
  
95 Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B et al. Gut flora metabolism of 
phosphatidylcholine promotes cardiovascular disease. Nature 2011; 472: 57– 63. 
  
96 Wegorzewska MM, Glowacki RWP, Hsieh SA, Donermeyer DL, Hickey CA, Horvath SC et al. Diet 
modulates colonic T cell responses by regulating the expression of a Bacteroides θιο antigen. Sci 
Immunol 2019; 4:eaau9079. 
  
97 Chai JN, Peng Y, Rengarajan S, Solomon BD, Ai TL, Shen Z et al. Helicobacter species are potent 
drivers of colonic T cell responses in homeostasis and inflammation. Sci Immunol 2017; 2. 
  
98 Kullberg MC, Jankovic D, Gorelick PL, Caspar P, Letterio JJ, Cheever AW et al. Bacteria‐triggered 
CD4+ T regulatory cells suppress Helicobacter hepaticus‐induced colitis. J Exp Med 2002; 196: 
505– 15. 
  
99 Xu M, Pokrovskii M, Ding Y, Yi R, Au C, Harrison OJ et al. c‐MAF‐dependent regulatory T cells 
mediate immunological tolerance to a gut pathobiont. Nature 2018; 554: 373– 77. 
  
100 Verma R, Lee C, Jeun EJ, Yi J, Kim KS, Ghosh A et al. Cell surface polysaccharides of 
Bifidobacterium bifidum induce the generation of Foxp3+ regulatory T cells. Sci Immunol 2018; 
3:eaat6975. 
  
101 Geuking MB, Cahenzli J, Lawson MA, Ng DC, Slack E, Hapfelmeier S et al. Intestinal bacterial 
colonization induces mutualistic regulatory T cell responses. Immunity 2011; 34: 794– 806. 
  
102 Tan TG, Sefik E, Geva‐Zatorsky N, Kua L, Naskar D, Teng F et al. Identifying species of symbiont 
bacteria from the human gut that, alone, can induce intestinal Th17 cells in mice. Proc Natl Acad Sci 
U S A 2016; 113: E8141– 50. 
  
103 Arpaia N, Campbell C, Fan X, Dikiy S, van der Veeken J, deRoos P et al. Metabolites produced by 
commensal bacteria promote peripheral regulatory T‐cell generation. Nature 2013; 504: 451– 5. 
  
104 Furusawa Y, Obata Y, Fukuda S, Endo TA, Nakato G, Takahashi D et al. Commensal microbe‐
derived butyrate induces the differentiation of colonic regulatory T cells. Nature 2013; 504: 446– 
50. 
  
105 Smith PM, Howitt MR, Panikov N, Michaud M, Gallini CA, Bohlooly‐Y M et al. The microbial 
metabolites, short‐chain fatty acids, regulate colonic Treg cell homeostasis. Science 2013; 341: 
569– 73. 
  
106 Kim M, Qie Y, Park J, Kim CH. Gut microbial metabolites fuel host antibody responses. Cell Host 
Microbe 2016; 20: 202– 14. 
  
107 Schulthess J, Pandey S, Capitani M, Rue‐Albrecht KC, Arnold I, Franchini F et al. The short chain 
fatty acid butyrate imprints an antimicrobial program in macrophages. Immunity 2019; 50: e7. 
  
108 Tan J, McKenzie C, Vuillermin PJ, Goverse G, Vinuesa CG, Mebius RE et al. Dietary fiber and 
bacterial SCFA enhance oral tolerance and protect against food allergy through diverse cellular 
pathways. Cell Rep 2016; 15: 2809– 24. 
  
109 Atarashi K, Nishimura J, Shima T, Umesaki Y, Yamamoto M, Onoue M et al. ATP drives lamina 
propria TH17 cell differentiation. Nature 2008; 455: 808– 12. 
  
110 Danne C, Ryzhakov G, Martínez‐López M, Ilott NE, Franchini F, Cuskin F et al. A large 
polysaccharide produced by Helicobacter hepaticus induces an anti‐inflammatory gene signature in 
macrophages. Cell Host Microbe 2017; 22: e5. 
  
111 Ladinsky MS, Araujo LP, Zhang X, Veltri J, Galan‐Diez M, Soualhi S et al. Endocytosis of 
commensal antigens by intestinal epithelial cells regulates mucosal T cell homeostasis. Science 2019; 
363:eaat4042. 
  
112 Kullberg MC, Ward JM, Gorelick PL, Caspar P, Hieny S, Cheever A et al. Helicobacter hepaticus 
triggers colitis in specific‐pathogen‐free interleukin‐10 (IL‐10)‐deficient mice through an IL‐
12‐ and γ interferon‐dependent mechanism. Infect Immun 1998; 66: 5157– 66. 
  
113 Lee YK, Menezes JS, Umesaki Y, Mazmanian SK. Proinflammatory T‐cell responses to gut 
microbiota promote experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 2011; 
108( Suppl 1): 4615– 22. 
  
114 Stepankova R, Powrie F, Kofronova O, Kozakova H, Hudcovic T, Hrncir T et al. Segmented 
filamentous bacteria in a defined bacterial cocktail induce intestinal inflammation in SCID mice 
reconstituted with CD45RBhigh CD4+ T cells. Inflamm Bowel Dis 2007; 13: 1202– 11. 
  
115 Wu HJ, Ivanov II, Darce J, Hattori K, Shima T, Umesaki Y et al. Gut‐residing segmented 
filamentous bacteria drive autoimmune arthritis via T helper 17 cells. Immunity 2010; 32: 815– 27. 
  
116 Al Nabhani Z, Dulauroy S, Marques R, Cousu C, Al Bounny S, Déjardin Fs. et al. A weaning 
reaction to microbiota is required for resistance to immunopathologies in the adult. Immunity 2019; 
50: e5. 
  
117 An D, Oh SF, Olszak T, Neves JF, Avci FY, Erturk‐Hasdemir D et al. Sphingolipids from a 
symbiotic microbe regulate homeostasis of host intestinal natural killer T cells. Cell 2014; 156: 123– 
33. 
  
118 Olszak T, An D, Zeissig S, Vera MP, Richter J, Franke A et al. Microbial exposure during early life 
has persistent effects on natural killer T cell function. Science 2012; 336: 489– 93. 
  
119 Chudnovskiy A, Mortha A, Kana V, Kennard A, Ramirez JD, Rahman A et al. Host–protozoan 
interactions protect from mucosal infections through activation of the inflammasome. Cell 2016; 
167: e14. 
  
120 Wullaert A, Lamkanfi M, McCoy KD. Defining the impact of host genotypes on microbiota 
composition requires meticulous control of experimental variables. Immunity 2018; 48: 605– 7. 
  
121 Letran SE, Lee SJ, Atif SM, Flores‐Langarica A, Uematsu S, Akira S et al. TLR5‐deficient mice 
lack basal inflammatory and metabolic defects but exhibit impaired CD4 T cell responses to a 
flagellated pathogen. J Immunol 2011; 186: 5406– 12. 
  
122 Vijay‐Kumar M, Sanders CJ, Taylor RT, Kumar A, Aitken JD, Sitaraman SV et al. Deletion of TLR5 
results in spontaneous colitis in mice. J Clin Invest 2007; 117: 3909– 21. 
  
123 Elinav E, Strowig T, Kau AL, Henao‐Mejia J, Thaiss CA, Booth CJ et al. NLRP6 inflammasome 
regulates colonic microbial ecology and risk for colitis. Cell 2011; 145: 745– 57. 
  
124 Lemire P, Robertson SJ, Maughan H, Tattoli I, Streutker CJ, Platnich JM et al. The NLR protein 
NLRP6 does not impact gut microbiota composition. Cell Rep 2017; 21: 3653– 61. 
  
125 Mamantopoulos M, Ronchi F, Van Hauwermeiren F, Vieira‐Silva S, Yilmaz B, Martens L et al. 
Nlrp6‐ and ASC‐dependent inflammasomes do not shape the commensal gut microbiota 
composition. Immunity 2017; 47: e4. 
  
126 Beura LK, Hamilton SE, Bi K, Schenkel JM, Odumade OA, Casey KA et al. Normalizing the 
environment recapitulates adult human immune traits in laboratory mice. Nature 2016; 532: 512– 6. 
  
127 Reese TA, Bi K, Kambal A, Filali‐Mouhim A, Beura LK, Bürger MC et al. Sequential infection with 
common pathogens promotes human‐like immune gene expression and altered vaccine response. 
Cell Host Microbe 2016; 19: 713– 9. 
  
128 Rosshart SP, Vassallo BG, Angeletti D, Hutchinson DS, Morgan AP, Takeda K et al. Wild mouse 
gut microbiota promotes host fitness and improves disease resistance. Cell 2017; 171: e13. 
  
129 Wymore Brand M, Wannemuehler MJ, Phillips GJ, Proctor A, Overstreet AM, Jergens AE et al. 
The altered schaedler flora: continued applications of a defined murine microbial community. ILAR J 
2015; 56: 169– 78. 
  
 
 
 
  
